This phase II trial studies the side effects of erlotinib hydrochloride and how well it works
in reducing duodenal polyp burden in patients with familial adenomatous polyposis at risk of
developing colon cancer. Erlotinib hydrochloride may stop the growth of tumor cells by
blocking some of the enzymes needed for cell growth.
Erlotinib Hydrochloride, Erlotinib
Attenuated Familial Adenomatous Polyposis, Familial Adenomatous Polyposis